For their November/December 2016 issue, Pharmaceutical Outsourcing Magazine interviewed Chris Bohl, PhD, Global Technical Support Manager for SEKISUI XenoTech’s Products Division, on the company and what’s new. Here’s an exerpt from the article about our new lysosomes and tritosomes:
Regarding products offered, can you tell us specifically what lysosomes are and how they can be used to be a more cost effective and accurate in vitro test system to monitor the stability/catabolism of targeted biotherapeutics that enter cells through the endosomal-lysosomal pathway?
Lysosomes are membrane-bound cellular organelles that are the site of degradation / catabolism of extracellular substrates (endocytic pathway) and intracellular substrates (autophagy pathway). Lysosomes contain a multitude of acidic hydrolytic enzymes and have isopycnic densities similar to mitochondria. Tritosomes are lysosomes isolated from Tyloxapol-treated animals for improved separation of the organelle from the mitochondria, and consequently, high specific activity of its catabolic enzymes.
Considering their unique pH and the presence of a variety of catabolic enzymes, therapeutic strategies are being designed to take advantage of lysosomes as the primary site of catabolism/activation for targeted biopharmaceuticals that enter cells through the endosomal-lysosomal pathway, such as ADCs, siRNA/RNAi molecules, immunotherapeutics, biodegradable copolymers and nanoparticles, etc…
Read the full interview here (pg. 23)
Learn more about:
About the Authors
Subscribe to our Newsletter
Stay up to date with our news, events and research
Do you have a question or a request for upcoming blog content?
We love to get your feedback